Candesartan Cilexetil Tablet Coating for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Candesartan cilexetil, an angiotensin II receptor antagonist, is unstable in tablet form, particularly during long-term storage, leading to the formation of undesirable by-products like desethyl candesartan, which reduces the active ingredient content, and it is challenging to determine the contribution of additives to this degradation.
Innovation Solution
A solid pharmaceutically active composition where the surface of candesartan cilexetil is coated with a mixture of tri(C1-C6)alkyl citrate, di(C1-C6)alkyl phthalate, di(C1-C6)alkyl sebacate, and polydimethylsiloxanes, with these compounds forming at least 40% of the coating, stabilizing the active ingredient both in the starting mixture and the tablet, preventing disintegration even after long storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If candesartan cilexetil is formulated as a tablet with conventional additives, then the tablet can be manufactured and administered orally, but the active ingredient degrades during long-term storage forming undesirable by-products
Solution Approach 1:
The patent introduces a coating layer comprising tri(C1-C6)alkyl citrate, di(C1-C6)alkyl phthalate, di(C1-C6)alkyl sebacate, and polydimethylsiloxanes as an intermediary substance between the active ingredient and the tablet matrix. This coating layer acts as a protective barrier that prevents direct interaction between candesartan cilexetil and conventional tablet additives, thereby eliminating degradation while maintaining manufacturability.
Solution Approach 2:
The patent applies a thin film coating to the surface of candesartan cilexetil particles before tablet compression. This flexible protective shell, composed of specific ester and silicone compounds, encapsulates the active ingredient and provides physical protection against degradation mechanisms during storage and processing.
2Stability of the object's composition
If the surface of candesartan cilexetil is coated with a protective layer, then stability during storage is improved, but the coating process adds complexity to manufacturing
Solution Approach 1:
The coating of candesartan cilexetil with the protective composition is performed as a preliminary step before tablet compression. By pre-coating the active ingredient particles, the stability problem is solved in advance, and the coated particles can be directly incorporated into the tablet manufacturing process without requiring additional coating equipment or complex multi-step procedures.
Solution Approach 2:
The patent specifies particular parameter ranges for the coating compounds (tri(C1-C6)alkyl citrate, di(C1-C6)alkyl phthalate, di(C1-C6)alkyl sebacate, and polydimethylsiloxanes) to optimize both stability and manufacturability. These parameter specifications ensure that the coating provides adequate protection while remaining compatible with conventional tablet processing conditions.
Data Source
AI summary
Composition in the form of a tablet, comprising candesartan cilexetil and optionally further active agents and usual adjuncts, wherein the surface of at least the active agent candesartan cilexetil in this composition is provided with a coating, made from a compound or a mixture of compounds selected from tri-(C1-C6) alkyl citrate, di-(C1- C6) alkyl phthalate, di-(C1-C6) alkyl sebacate and polydimethysiloxanes and methods for production thereof.